% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Kseer:274217,
      author       = {A. S. Köseer and S. Di Gaetano and C. Arndt and M.
                      Bachmann$^*$ and A. Dubrovska$^*$},
      title        = {{I}mmunotargeting of {C}ancer {S}tem {C}ells.},
      journal      = {Cancers},
      volume       = {15},
      number       = {5},
      issn         = {2072-6694},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DKFZ-2023-00503},
      pages        = {1608},
      year         = {2023},
      abstract     = {The generally accepted view is that CSCs hijack the
                      signaling pathways attributed to normal stem cells that
                      regulate the self-renewal and differentiation processes.
                      Therefore, the development of selective targeting strategies
                      for CSC, although clinically meaningful, is associated with
                      significant challenges because CSC and normal stem cells
                      share many important signaling mechanisms for their
                      maintenance and survival. Furthermore, the efficacy of this
                      therapy is opposed by tumor heterogeneity and CSC
                      plasticity. While there have been considerable efforts to
                      target CSC populations by the chemical inhibition of the
                      developmental pathways such as Notch, Hedgehog (Hh), and
                      Wnt/β-catenin, noticeably fewer attempts were focused on
                      the stimulation of the immune response by CSC-specific
                      antigens, including cell-surface targets. Cancer
                      immunotherapies are based on triggering the anti-tumor
                      immune response by specific activation and targeted
                      redirecting of immune cells toward tumor cells. This review
                      is focused on CSC-directed immunotherapeutic approaches such
                      as bispecific antibodies and antibody-drug candidates,
                      CSC-targeted cellular immunotherapies, and immune-based
                      vaccines. We discuss the strategies to improve the safety
                      and efficacy of the different immunotherapeutic approaches
                      and describe the current state of their clinical
                      development.},
      subtyp        = {Review Article},
      keywords     = {CAR-T cells (Other) / CSC (Other) / bsAB (Other) / cancer
                      stem cells (Other) / cancer vaccines (Other) / immunotherapy
                      (Other)},
      cin          = {DD01},
      ddc          = {610},
      cid          = {I:(DE-He78)DD01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36900399},
      doi          = {10.3390/cancers15051608},
      url          = {https://inrepo02.dkfz.de/record/274217},
}